Veracyte Inc (VCYT) Q4 2025 Earnings Call Transcript

Why It Matters

The results underscore Veracyte’s ability to scale its molecular diagnostics while maintaining profitability, positioning it for continued double‑digit growth and expanding market share in oncology testing.

Key Takeaways

• Revenue $140.6M, up 19% YoY.
• Testing margin 76.1%, up 380 basis points.
• Decipher ordering physicians increased 18% year over year.
• Afirma moved to v2 transcriptome, cutting no‑result rate.
• 2026 guidance: $570‑$582M revenue, ~25% EBITDA margin.

Pulse Analysis

Veracyte’s Q4 performance highlights the resilience of its core diagnostic platform amid a competitive molecular testing landscape. By leveraging the v2 transcriptome technology, the company reduced assay costs and improved result yield, which translated into higher average selling prices and a notable expansion of gross margins. This operational upgrade not only boosts short‑term profitability but also creates a scalable foundation for future test development, reinforcing Veracyte’s strategic focus on cost‑effective, high‑value diagnostics.

The firm’s growth is further propelled by robust adoption of its flagship Decipher and Afirma assays. Decipher’s physician network grew 18% YoY, and test volumes surged 21%, reflecting deepening integration into NCCN‑endorsed care pathways. Meanwhile, Afirma’s transition to the v2 platform lowered the no‑result rate, enhancing clinician confidence and supporting market‑share gains in thyroid nodule evaluation. These dynamics, combined with a strong cash position of $413 million, give Veracyte flexibility to invest in pipeline expansion without diluting shareholder value.

Looking ahead, Veracyte’s 2026 outlook is anchored by two high‑impact product launches: TRUE MRD for muscle‑invasive bladder cancer and the Prosigna LDT for early‑stage breast cancer. Both address unmet clinical needs and leverage the company’s extensive genomic data assets, positioning Veracyte to capture new revenue streams beyond its existing oncology portfolio. The guidance of $570‑$582 million revenue and a 25% adjusted EBITDA margin signals confidence in sustaining double‑digit growth while delivering shareholder‑friendly returns.